ir.navidea.com, for thank webcast here website, slide will deck and displayed. an you, also There joining made live a available. be you our that being Thank accompanying is all us is replay call today. on being is and This
and of Following prepared of conducting Vice Board and Directors, of be Mr. its me Eves, Cappello, Chair, question-and-answer are it's President live today. on remarks, a we its Kim Erika Administration, the Scott Mr. Finance will Chair session. Vice Alex joining Navidea's call
regulatory During call, the Navidea's forward-looking future making of business events the and the molecular statements diagnostics of our course develop These company. this we will to performance events relate conference regarding future to be pandemic plans include as and operations. Navidea's readouts, strategic which clinical data resources and COVID-XX with well matters, as immunotherapeutics, the of on clinical along of timing capital and business impact developments the and
in SEC. read with update. company's information, of filings the included let's and safe the the of most future our as actual to results statements update materially. certain uncertainties whether annual carefully or cause are harbor could recent that, and the All These result website, statements, Investors of events assume new a no and the of We or uncertainties begin otherwise. assumptions, as risks factors and should forward-looking involve management risk beliefs based section to of statements today. revise risks as quarterly and the these described within With on as our obligation well expectations differ
month, on offering. issued of loans of and closed arm of exercisable company X $XX.X company. issuance Board If completed rights banking company's XXXX price the approximately Chair from with an on The be received Directors, exercise of of are And second work offering a offering. $X.X $X.X quarter years During exercised, additional since, The the the we million last company investment bridge Scott. of may cash We Mr. Maxim proceeds per rights continue of the Vice the of warrants the the the Group. up million to for the financing in in have exercise shar. expire gross and from the $X.XX date of million gross proceeds immediately, warrants aggregate through to received
reimbursement also payment certain of for strategic and received a research from accelerated an development $XXX,XXX We partner. expenses
We in continue to months. the plan raise capital for additional coming
we've fibroid indications from hypotheses results clinical advanced preliminary well strong in our support therapeutics. arthritis, in provide data biopsy, RA, announced trials the Overall, our progress imaging We to pathotype rheumatoid to and patients. of on results expression and great our IIb arthritis, our Phase joints ability and support rheumatoid have distinguish with made as our CDXXX evaluated comparing other patients early or is promising non-fibroid These fulmanocept and XX as we and in of in RA. good imaging diagnostic of first our the biomarker pipeline in and trial a
and III have opened XX X for total continue also sites recently a into Phase open. an to RA enroll up We the additional now
efficiently and here also works investigators intellectual this be proud are and and hard to across institutions and outstanding the associated imaging our various with company's very applications individuals. are well-known we The team We through with property. I'm collaborative therapeutics of relationships advancing growing globe, maintaining group and extremely diligently and the
potential have the our continued the product the of MoU carried understanding. other recent parties This terms about potential memorandum original we You signing time into claims From tilmanocept or termination of we announced Phase of case, breach opportunity Therapeutics. with Jubilant such in may awarding advanced trials Capital Royalty could commercial we attorney a the exclusivity from entertain speak the Phase ruling underway. have a to memorandum rights In against advance of currently Macrophage Group seen to discussions CRGs our their fees that in the and of in significant of the with to period Navidea on exclusivity, for release advising to the is ending RA not the partners now, to III of The RA. offers and data IIb hand. contract
this law in disappointed believe and the the the court's trial are We presented and not ruling support do at ruling. facts the
of We response action are in this to course to pursue discussing our ruling. best
in soon you past, scenes, provide and are there we things the updates working behind able said as recent appropriate. we've the are As as as with on will we many we and are
Now rheumatoid arthritis to with our detail more in around provide I'd clinical program. begin the progress I'll like updates.
We continue III Phase in our trial RA. to enroll into
mentioned, I X recently to months have have date. we As just We've August sites that the we done opened announced with at up enrollment. enrolled new and subjects XX XX site about total of end this
rate enrollment new first-time we greater alpha with than level of indications localization RA to prediction a patients month per to the going or in average. The site, one, forward again, are alpha less therapy. two, low likely are to therapy and treatment RA once per significantly anti-TNF of to our respond response of is anti-TNF early tilmanocept are So of identification
not unmet is in if whether a bring because not for is along long-term patient for have or a early is treated, there high effects. consequences working, we a of working need RA reliable costs unnecessary and can with As drug therapy to them health possible that the patient's not discussed therapies drug with a disease side previously, lead ineffective with predictor this being large is
establish will biopsy, treatment trial unmet to this therapy, this of RA of in III an recruitment. anti-TNF alpha to In predictor need. tilmanocept study our Phase in addressing response early imaging NAVX-XX, an patients trial imaging the serve tilmanocept as switching XXm active medical comparison technetium ability remains of Our
discussed and announced of results this are we've preliminary trial the As previously, promising.
enroll comparative minimum imaging RA four of myeloid pathology and and myeloid. so is each in RA, three obtain subjects patients to of pathotypes the is to of that the recruit pathotypes of aim fibroid, diffuse three trial Our and with each results these a we lymphoid of designed
expected tissue. XX. joint has the patients achieved to type type less be fibroid at between assess to in which range values of relationship the are anti-TNF we suggesting To patients to been size literature overall So biopsies between a growing of the is important patient There the or out may individual RA RA buckets body pathotypes both joint-specific responsive minimum passive our is imaging predict\to more drugs. and the RA The completed. of patients to and with joint RA XX pathobiology a is of much study two Knowledge date, to objective having have it three of trial of primary uptake of tilmanocep clinically because may respond. likely involved an with the that those therapy alpha the
has is And opinion so of seen to important as particular in patient a leaders key pathotypeis means a extremely a rheumatology. determining not this whether or of number
in one differentiate As with involvement or by These subjects, information. mentioned with from on preliminary of diffuse having X of RA this an i.e., time, RA, XX those the the the those the pathotypes Of patients. on myeloid. of to have high those either and of patient's myeloid subjects average, i.e., pathotypes. of X with of And macrophage these subjects fibroid tilmanocep tilmanocep patients results pathotypes had the subjects pathotypes the had to X discretely involvement. doing the more fibroid X joints X the that the inflamed invasive than there uptake We able a relatively of lympho lymphomyeloid as is uptake results I low uptake. the tilmanocep fibroid indicated had one could Furthermore, X we macrophage other times remaining diffuse the is pathotypes first with way no myeloid were subject low the with than assessing previously found the hypothesized those biopsy. of pathotype. pathotype RA this provide All either discussed levels average that these have tilmanocep those reliable that have
able likely in alone, we cases. the imaging from meaningful alpha to support also Phase an I those classify predict increasing receive to there's before a of been clearly therapy. mentioned, evidence data RA from XX patient to non-fibroid taken is less fibroid anti-TNF pathotype a of anti-TNF our clinical Since that These are either a whether ability they or clinical for has to therapy. patient benefit benefit the from patients the likely So in indications as as results significant III a biopsy based scan on baseline a if our receive alpha have one fibroid provide trial,
uptake response, non-response in You scan efficacy those gold of XXX, anti-TNF the clinical a joints of study, had their at early IIb on a prediction level tilmanocep low to almost using Phase in alpha patients arm XX% of assessment. imaging at tilmanocep rate might exhibiting standard our completed an that treatment the looking contained recall pilot previously baseline their NAV therapy
You results previous an can look NAV full conference, from to IIb for these be presented this preliminary along Phase XX. with results study upcoming study at
fact, biopsy faster what rate overall slow in recruiting, Finally, sites notoriously our would indicated than but PI of recruitment these lead is are number trials our he expect.
XX XX first months. enrollment Due and our COVID for achieve that about recruitment, of phase, able we figures date of as sites in to opening open XX could have could of now open we in parts planning only our if from sites is X were enrollment Specifically, issues, been told in resources, months. as for we site well our to to X reopening large the
expectations team clinical a the job same completed a enrollment with the has time exceeding the where great period sites. done at roughly in almost third of usual, As we've
make well, the product. for to significant automating commercial We very in will progress as image benefit the have continue good quantification which
mind commercial that you've only the as read critical at most automated through to to arthritis. the to Keep it not the heard is to serves before, can competitors and but based as ability of and is us built, objective quantitative all on the image our which space. also agreement the well reproducibly medical the entry of demonstrating data Cleveland rheumatoid a the They footprint continue significant product. imaging as imaging image large large sensitive a for again, in using tilmanocept of a upon driving using scale images, rapidly perform analysis our fully pilot and company nuclear barrier to accurate of software and discos have in software automated We our in imaging a be be tilmanocept of our quantitative RA. from for completed full MIM space. for closely medicine proprietary rollout results our intent reproduce trials data quantification that Once study can work commercial that the MIM for algorithm. with to with is important a them they application this leading letter possible it use this, is develop in including large-scale methodology, partner The normative will means in reads critical to database robustly This of a
atherosclerotic has we'll with investigator-initiated center we help work of the agents manifest are [ph] plaque internal that have to Preclinical tilmanocept continue will or work to terms support, disease, them Gallium at collaboration finalize development reference General Navidea and and sites when pilot studies the the publication, for the Hospital the of on previously. the XX other released MIM in to In press at Massachusetts find progressed localization and with at the plaque and in there. of significantly what of terms make cardiovascular with Birmingham through in line imaging Alabama areas promising can was of co-published published and PET in done. at imaging University were through announcement atherosclerotic imaging UAB. tomato our an diagnostics researchers study We data extramural in Boston, you next-generation it group results the reported to with we the of pipeline to of We partnership study related
looked imaging to successful, evaluating NIH-funded increase and on work our and tilmanocept agent to the recent for manuscript at we blocking Gallium Medicine Molecular in imaging the the imaging XX meeting to tilmanocept tilmanocept a preclinical off-target liver, agent studies review. currently imaging the another on work localization which new a and These simultaneously various additional were localization is can technology when localization important new agent block was mouse atherosclerosis. increase showing of presented localization to site to intravenously. of of of completed have model tissues, highly localization target major while was to dramatically our agents a tilmanocept to We that and studies similar while Nuclear Society in We're studies the at a of like set tumors, peer significantly Imaging method imaging preclinical is This administered liver. off-target designed is completed
effective oncology studies. front, assets therapeutic and or anti-inflammatory in the of tumor the of constructs for than that constructs drug, candidates may drug doxorubicin beneficially on alone in the when constructs On altering another growth. therapeutic carry our payloads status mouse These targeted macrophages, in progressed. new administered significantly drug cancer new the has reduce spaces immune delivery advancing demonstrated Work tumor these have more models example. combination for Results payloads new rate we new preclinical and that in with are be
humans examining of these Some area Therapy parts indications. the a macrophage lead advancing and drugs where were constructs expressing preclinical promising leaders published the in work constructs new is This our Southern replication phenotype of are bisphosphonate of Summit recently and studies soon studies. for Tumor tested found, demonstrating inflammatory altering as well. more found study about to the U.S., of macrophages but disease. change. one role the serious is Directed Europe. ability rare CDXXX this potentially ongoing the is to infected in is in at It life-threatening vitro is for it Leachman in a meeting and early transmitted preclinical payload covering macrophages. as ISS macrophage candidate form X dominant third the sandlifound results And disease high presented ISS of in with then dexamethasone a Myeloid a that These subtropic caused countries In We demonstrating results vectors for [ph] also will be vector XXXX, chronic are Leachman a preclinical that studies constructs world play we in positive disease. by protozoa shown have bite Leachman the replicates currently parasite have is tropical sandflies indications borne CDXXX-positive ISS in of from in phenotype underway. Preclinical models. recently, renewed A work in the well, common studies through oncology the tropics,
And therapeutic We front. is so for application to patents the property brings and received therapeutic of U.S. our notification our for robust pipeline covering Leachman PTO me patent intellectual a our forward. Manocept-based moving of ISS. overall issuance from That
submit applications to provisional We work new pending and continue well. applications our as on
We and for constructs mentioned a and containing preclinically filed provisional therapeutic ago. studies have the other new inflammatory linker one for describing effects bisphosphonate and in model applications, describing a These construct new evaluated are Manocept Manocept macrophages two minutes indications. constructs on dexamethasone patent I in using degradable being animal paclitaxel-containing oncology few of
total We in have since provisional filed new XX, December five XXXX. patents
received of We platform-based payloads to to [ph] wide constructs degradable a related targeted of for patent application claims hydrophone of also decision Manocept delivery attached a therapeutic for a grants in range Linker. Japan using
our therapeutic and we we will to molecules next-generation our IP So strategy as active disease have that protections both an needed diagnostic and provide rights current and protection as to indications. well agents,
RA product, as API Lymphoseek supply work a new the as and active drug or the the with and supplier. we pharmaceutical product both supplier, and continue front to on ingredient well have drug for Now final manufacturing been
you time, to for towards will are this progresses. clinical up We these and But as we and commercial this supply forward. date readiness advancing as going completion of keep of
was On seen the publication an Australian our using the colleagues investigator forward. might are and of this recent coming about out tilmanocept. Lymphoseek a Lymphoseek This and announcing Australia his study of in have release going investigator World press Australia Europe front, enthusiastic the of by using manuscript Rest and you first
partner. progress RA pricing our writing a and indications, III, with is biopsy focused potentially strengths are other the but remain possibilities market of the pipeline on opportunity for we quarter highlights for penetrating push of wanted challenges well. touch last indications. licensing in the the as with excellent studies largely of Prior and the long-term IIb diagnostic node continue appropriate other pricing that the also discussions on are to to trial the Lymphoseek we lymph with to just an demonstrating We for These about number and Phase diagnostic of also while on sentinel support We competition, there were specifically and Lymphoseek the early relationship imaging therapeutic that Europe we products update. this in Phase and there pipeline, feel some
team I moving As things trial efforts keep research always, to here the collaborators and for thank network hard want tireless to for of of clinical and all academic their our work. their sites
commercialization appropriate to seek and inflection for Our key strategy advance products our marketing. partnerships to and remains pipeline points
you. financial like thank that, Erica the So With to the to call Erika? I'd turn updates. over for
